SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment

Synthetic lethality exploits the phenomenon that a mutation in a cancer gene is often associated with new vulnerability which can be uniquely targeted therapeutically, leading to a significant increase in favorable outcome. DNA damage and survival pathways are among the most commonly mutated networks in human cancers. Recent data suggest that synthetic lethal interactions between a tumor defect and a DNA repair pathway can be used to preferentially kill tumor cells. We recently published a method, DiscoverSL, using multi-omic cancer data, that can predict synthetic lethal interactions of potential clinical relevance. Here, we apply the generality of our models in a comprehensive web tool called Synthetic Lethality Bio Discovery Portal (SL-BioDP) and extend the cancer types to 18 cancer genome atlas cohorts. SL-BioDP enables a data-driven computational approach to predict synthetic lethal interactions from hallmark cancer pathways by mining cancer’s genomic and chemical interactions. Our tool provides queries and visualizations for exploring potentially targetable synthetic lethal interactions, shows Kaplan–Meier plots of clinical relevance, and provides in silico validation using short hairpin RNA (shRNA) and drug efficacy data. Our method would thus shed light on mechanisms of synthetic lethal interactions and lead to the discovery of novel anticancer drugs.

[1]  Xiang Deng,et al.  DiscoverSL: an R package for multi‐omic data driven prediction of synthetic lethality in cancers , 2018, Bioinform..

[2]  Li Ding,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018) , 2018 .

[3]  E. Ruppin,et al.  Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.

[4]  Reena Philip,et al.  FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations , 2018, The oncologist.

[5]  Alex H. Wagner,et al.  DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.

[6]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[7]  Mark D. M. Leiserson,et al.  Precision Oncology: The Road Ahead. , 2017, Trends in molecular medicine.

[8]  R. Bernards,et al.  A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. , 2017, European urology.

[9]  G. Mills,et al.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.

[10]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[11]  Hui Liu,et al.  SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets , 2015, Nucleic Acids Res..

[12]  Andrea Bild,et al.  Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results , 2015, Bioinform..

[13]  Gaurav Pandey,et al.  Prediction of Genetic Interactions Using Machine Learning and Network Properties , 2015, Front. Bioeng. Biotechnol..

[14]  L. Wong,et al.  Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer , 2015, Biology Direct.

[15]  W. Sellers,et al.  Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.

[16]  Ellen T. Gelfand,et al.  Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.

[17]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[18]  P. Goodfellow,et al.  Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .

[19]  J. Hoheisel,et al.  High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells , 2014, BMC Genomics.

[20]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[21]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[22]  Julian Downward,et al.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies , 2012, Cell Research.

[23]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[24]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[25]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[26]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[27]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[28]  Alan Ashworth,et al.  Searching for synthetic lethality in cancer. , 2011, Current opinion in genetics & development.

[29]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[30]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[31]  A. Ashworth,et al.  A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.

[32]  W. Kaelin,et al.  Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen , 2008, Proceedings of the National Academy of Sciences.

[33]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[34]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[35]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[36]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[37]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.